HIGHLIGHTS
- who: Christopher Kjaer Cullum from the Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark have published the research: Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study, in the Journal: (JOURNAL)
- what: This study assessed the long-term efficacy and safety of erenumab in a 52-week, single-center, prospective, observational study that includes adult patients with chronic migraine who are eligible for treatment with mAbs against CGRP or its receptor in Denmark. The study has several limitations . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.